Hoffmann-La Roche

Spark Therapeutics Enters Into Strategic Collaboration with Neurochase for Use of Proprietary Delivery Technology for CNS Disorders

Retrieved on: 
Friday, January 27, 2023
CNS, AAV, Traffic barrier, Central nervous system disease, Spark Therapeutics, ROG, Central nervous system, Patient, RO, CED, Biological Technologies Office (DARPA), Huntington's disease, Hoffmann-La Roche, Degenerative disease, Brain, Research, Therapy, Pharmaceutical industry, Medical device, Spark

Through this collaboration, Neurochase will bring their deep expertise in direct drug delivery technology to Spark’s leading AAV platform.

Key Points: 
  • Through this collaboration, Neurochase will bring their deep expertise in direct drug delivery technology to Spark’s leading AAV platform.
  • "There continues to be high unmet medical need in treating CNS disorders, and at Spark we see the significant potential of gene therapy to provide new treatment options for patients," said Federico Mingozzi, Chief Science & Technology Officer, Spark Therapeutics.
  • Neurochase is developing a proprietary drug delivery system and this collaboration enables Spark to develop selected gene therapies for CNS disorders using the Neurochase technology, which aims to improve targeted delivery of AAV gene therapy to neural structures using the method of Convection Enhanced Delivery (CED).
  • "Applying CED-based delivery systems for AAV gene therapies is an emerging strategy for the treatment of neurological disorders," said Sharon Kane, CEO, Neurochase.

Genentech’s Tecentriq Plus Avastin Is the First Treatment Combination to Reduce the Risk of Cancer Returning in People With Certain Types of Early-Stage Liver Cancer in a Phase III Trial

Retrieved on: 
Thursday, January 19, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Disease, Bevacizumab, Hoffmann-La Roche, RO, Regulation of tobacco by the U.S. Food and Drug Administration, Safety, Breast, Risk, Skin, Lung, Partnership, Food, Patient, European Medicines Agency, RFS, Mortality, HCC, Liver cancer, Recurrence, Head, ROG, Phase, Incidence, Pharmaceutical industry, Medical imaging, Atezolizumab, Genentech

The study is evaluating Tecentriq® (atezolizumab) in combination with Avastin® (bevacizumab) as adjuvant treatment following surgery for people with early-stage hepatocellular carcinoma (HCC) at high risk of disease recurrence.

Key Points: 
  • The study is evaluating Tecentriq® (atezolizumab) in combination with Avastin® (bevacizumab) as adjuvant treatment following surgery for people with early-stage hepatocellular carcinoma (HCC) at high risk of disease recurrence.
  • Overall survival data were immature at the time of interim analysis and follow-up will continue to the next analysis.
  • Safety for Tecentriq and Avastin was consistent with the known safety profile of each therapeutic agent and with the underlying disease.
  • IMbrave050 is part of Genentech’s overall commitment to drive fundamental treatment change and improve outcomes for people living with liver cancer.

Kronos Bio Announces Discovery Collaboration with Genentech to Advance Novel Therapies Against Transcriptional Targets in Oncology

Retrieved on: 
Monday, January 9, 2023
Hoffmann-La Roche, SMM, Kronos, Partnership, Factor X, Biology, Patient, Genentech, KRON, Research, Cancer, SAN, Fine chemical, Pharmaceutical industry

SAN MATEO, Calif. and CAMBRIDGE, Mass., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, announced today that it has entered into a discovery collaboration in the field of oncology with Genentech, a member of the Roche Group, focused on discovering and developing small-molecule drugs that modulate transcription factor targets selected by Genentech.

Key Points: 
  • The partnership will allow Genentech to leverage Kronos Bio’s expertise to identify protein-protein interactions, genetic dependencies and gene expression signatures to better understand and target the oncogenic activity of transcription factors in cancer types of interest.
  • Under the collaboration, researchers at the two companies will collaborate using Kronos Bio’s proprietary drug discovery platform, including the small molecule microarray (SMM) for hit finding, to build upon research conducted to date by Genentech.
  • “We are pleased to be able to leverage our unique platform to collaborate with Genentech to further Kronos Bio’s understanding of transcription-driven oncogenesis and ability to identify novel targets involved.”
    Kronos Bio will lead discovery and research activities to a defined preclinical point when Genentech will have the exclusive right to pursue further preclinical and clinical development and commercialization.
  • “We are excited about the possibilities that this collaboration with Kronos Bio brings to further our understanding of complex scientific networks with the goal of bringing highly effective medicines to patients,” said James Sabry, Global Head of Roche Pharma Partnering.

Global Genetic Diagnostics Market Report 2023: Rising Number of Genetic Disorders Stimulates Growth - ResearchAndMarkets.com

Retrieved on: 
Monday, January 9, 2023
Health, Genetics, Disease, Genetic testing, International System for Human Cytogenetic Nomenclature, Prenatal development, QIAGEN, Cancer, Parent, Porter W Anderson Jr., Government, Porter's five forces analysis, Thermo Fisher Scientific, Competition, Cytogenetics, Illumina, Inc., Organization, Growth, Abbott Laboratories, Patient, SWOT, Mortality, Quest Diagnostics, Myriad Genetics, Hoffmann-La Roche, USD, Genetic disorder, COVID-19, Danaher Corporation, Pharmaceutical industry, Medical device, Application

The genetic diagnostics market is driven by a rising number of genetic disorder cases.

Key Points: 
  • The genetic diagnostics market is driven by a rising number of genetic disorder cases.
  • The report analyses the Genetic Diagnostics Market By Type (Predictive and Presymptomatic Testing, Diagnostics Testing, Prenatal and Newborn Testing, Pharmacogenetic Testing, Other Application).
  • The report analyses the Genetic Diagnostics Market By Application (Cancer Diagnosis, Genetic Disease Diagnosis, Cardiovascular Disease Diagnosis, Other Application).
  • The Global Genetic Diagnostics Market has been analysed by countries (United States, Canada, Germany, UK, France, Spain, China, Japan, India, Australia).

Azafaros Strengthens Medical and Scientific Management Team Reflecting Clinical Progress

Retrieved on: 
Monday, January 9, 2023
Health, Other Health, Other Science, Clinical Trials, Science, Pharmaceutical, Biotechnology, IND, Drug development, BTG, GM1, FDA, Collection, Natural history, Head, Hoffmann-La Roche, Fast Track, Patient, CNM, Niemann–Pick disease, Centronuclear myopathy, GM2, Pharmaceutical industry, Health, Other Health, Other Science, Clinical Trials, Science, Pharmaceutical, Biotechnology

Dr. Christian Freitag joins the company as Chief Medical Officer and Dr. Kyle Landskroner has been promoted to Chief Scientific Officer.

Key Points: 
  • Dr. Christian Freitag joins the company as Chief Medical Officer and Dr. Kyle Landskroner has been promoted to Chief Scientific Officer.
  • With their comprehensive expertise in clinical and early-stage drug development, they will support the transition of Azafaros’ lead program, AZ-3102, into late-stage clinical evaluation and the expansion of Azafaros’ pipeline.
  • Prior to joining Azafaros, Dr. Freitag was Chief Medical Officer at Dynacure, where he was responsible for medical and regulatory strategy, including clinical development of the lead compound in Myotubular and Centronuclear Myopathies (CNM).
  • Christian Freitag, Chief Medical Officer of Azafaros, commented: “Joining Azafaros at this time is very exciting.

Xencor Highlights 2023 Corporate Priorities and Provides Portfolio Updates

Retrieved on: 
Monday, January 9, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, IND, Degenerative disease, Autoimmune disease, Janssen, Hoffmann-La Roche, Ipilimumab, Lymphoma, Ovarian cancer, Monoclonal antibody, Janssen Biotech, Bispecific monoclonal antibody, CD28, Cytokine, ICOS, Tumor microenvironment, Psoriasis, ENPP3, RCC, Biology, CLDN6, NK, Immune system, Protein engineering, Ligand, Patient, Genentech, CD3, Atopic dermatitis, Research, Cancer, Claudin, CLDN9, Antibody, Lenalidomide, MCRPC, Vaccine, Pharmaceutical industry, Medicine, Medical imaging, Regulatory T cell

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced 2023 corporate priorities and provided multiple clinical development updates.

Key Points: 
  • Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced 2023 corporate priorities and provided multiple clinical development updates.
  • “We are building on this momentum in 2023, progressing our clinical portfolio internally and with our co-development partners, including four bispecific antibody programs targeting solid tumors.
  • Xencor plans to:
    Continue enrolling patients into the Phase 1b, multiple-ascending dose study in patients with atopic dermatitis and psoriasis.
  • Xencor ended the fourth quarter of 2022 with unaudited cash, cash equivalents, receivables and marketable debt securities totaling approximately $610 million.

Acute Migraine Treatment Market Value to Exceed US$ 7.9 Billion by 2031, Reveals Transparency Market Research

Retrieved on: 
Wednesday, January 11, 2023
Migraine, Eli Lilly and Company, AbbVie, Pacific Ocean, Disease, Hoffmann-La Roche, Merck & Co., Pfizer, Teva Pharmaceuticals, Traction, Risk, Johnson & Johnson, Patient, AstraZeneca, Novartis, OTC, CGRP, Prevalence, Allergan, Incidence, US, TMR, Pharmaceutical industry

Availability of affordable treatments for migraine and its symptoms has broadened the acute migraine treatment market outlook.

Key Points: 
  • Availability of affordable treatments for migraine and its symptoms has broadened the acute migraine treatment market outlook.
  • The acute migraine treatment market size stood at US$ 2.1 Bn in 2021.
  • Recent acute migraine treatment market trends indicate that CGRP antagonists are emerging as an effective and convenient treatment for migraine and symptoms associated with acute migraine headache.
  • Key players strive to expand their product portfolio and engage in mergers and acquisitions in order to gain acute migraine treatment market shares.

Hestia Insight Inc. Appoints Advisory Board Member to Assist in Company Growth

Retrieved on: 
Thursday, January 5, 2023
West Virginia University, OTCQB, Hoffmann-La Roche, Merck & Co., Drug development, Merck, Barakat Pharmaceutical Group, Chaung-U, Growth, Massachusetts Institute of Technology, National Taiwan University, Bristol Myers Squibb, Virginia University, Marketing, Pharmaceutical industry

NEW YORK, NY, Jan. 05, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Hestia Insight Inc. (OTCQB: HSTA) (“Hestia Insight” and the “Company”), a company focused on the development and operation of novel technologies in the healthcare and biotech sectors, as well as providing sales and marketing guidance and capital markets advisory services to its clients, today announced its appointment of an additional advisory board member to assist in the growth of the Company.

Key Points: 
  • NEW YORK, NY, Jan. 05, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Hestia Insight Inc. (OTCQB: HSTA) (“Hestia Insight” and the “Company”), a company focused on the development and operation of novel technologies in the healthcare and biotech sectors, as well as providing sales and marketing guidance and capital markets advisory services to its clients, today announced its appointment of an additional advisory board member to assist in the growth of the Company.
  • (Ted) Chaung, a seasoned independent healthcare consultant with broad experience in healthcare industry startups, new drug development, venture capital, and business development, in both the Taiwan and U.S. healthcare sectors, has joined the Company’s advisory board.
  • “We are excited to welcome the addition of Dr. Ted Chaung to our Advisory Board,”  stated Hestia Insight’s CEO and Chairman, Edward Lee.
  • We look forward to utilizing Dr. Chaung’s impressive background and skill set to assist with the growth of Hesta Insight.”

Replimune Appoints Former Sanofi U.S. Commercial Oncology Head, Chris Sarchi, as Chief Commercial Officer and Sushil Patel as Chief Strategy Officer

Retrieved on: 
Wednesday, January 4, 2023
Hoffmann-La Roche, IMS Health, Boehringer Ingelheim, Head, Genentech, University of London, Squamous cell carcinoma, RP1, RP2, Health, GSK, Skin, CSCC, RP3, University, Imperial College London, Center for Study of Science, Technology and Policy (CSTEP), Nursing, BCC, Marketing, Molecular biology, Management, Fine chemical, Sanofi, Biotechnology, Science, Medicine, Vismodegib, Biosimilar

“These leadership appointments provide broad strategic and operational commercial acumen as we ramp up our commercial planning ahead of the potential 2024 commercial launch of RP1,” said Philip Astley-Sparke, Chief Executive Officer of Replimune.

Key Points: 
  • “These leadership appointments provide broad strategic and operational commercial acumen as we ramp up our commercial planning ahead of the potential 2024 commercial launch of RP1,” said Philip Astley-Sparke, Chief Executive Officer of Replimune.
  • “Chris led the launch of Libtayo in cutaneous squamous cell carcinoma (CSCC) at Sanofi, and was also involved with the launch of Erivedge in basal cell carcinoma (BCC) when at Genentech.
  • Sush will partner with Chris on our go-to-market strategy in the U.S. with RP1 and also in defining our commercialization strategy for the rest of the world.
  • Chris began his career with GSK where he held several sales and marketing leadership roles of increasing responsibility.

CHARM Therapeutics Strengthens Leadership Team with Key Appointments to Support Drug Discovery and Development Capability

Retrieved on: 
Wednesday, January 4, 2023
Biomedicine, Hoffmann-La Roche, Khosla Ventures, Stanford University, D, Machine learning, Roivant Sciences, Agios Pharmaceuticals, Pfizer, Doctor of Philosophy, Drug discovery, Head, Research, General Catalyst, Publication, Biology, Master of Science, Medicine, The Tumor, University of Minnesota College of Food, Agricultural and Natural Resource Sciences, Intelligence, AMAG Pharmaceuticals, ARIAD Pharmaceuticals, 3D, Therapy, Drug development, Vertex, Deep learning, GSK, Toxicology, University, Family, Cancer Research UK, Cell, Senior, Weill Cornell Graduate School of Medical Sciences, Pharmacokinetics, Merck & Co., MBA, Data management, Moscow State University, Immersion, DPU, Medical device, Pharmaceutical industry, Management, Crystallography, Science, Health care, Economics, Pharmacology, AI, Nature

LONDON – 4 January 2023 -- CHARM Therapeutics (“CHARM”, “The Company”), a 3D deep-learning research Company discovering and developing transformational medicines, today announces the expansion of its leadership team with a series of key appointments to strengthen its drug discovery and development, as well as operational management capabilities.

Key Points: 
  • Enhanced leadership team brings strong AI and drug discovery expertise and experience, reinforcing CHARM Therapeutics’ existing R&D capabilities
    LONDON – 4 January 2023 -- CHARM Therapeutics (“CHARM”, “The Company”), a 3D deep-learning research Company discovering and developing transformational medicines, today announces the expansion of its leadership team with a series of key appointments to strengthen its drug discovery and development, as well as operational management capabilities.
  • These appointments will support CHARM as it builds out of its research and development function to advance discoveries driven by its proprietary 3D deep-learning engine towards development.
  • CHARM Therapeutics raised $50 million in a Series A financing round announced in 2022, led by F-Prime Capital and OrbiMed, with General Catalyst and Khosla Ventures.
  • Gary D. Glick Ph.D., Executive Chair of CHARM Therapeutics, commented: “The exceptional people joining CHARM bring the perfect combination of skills, from immersion in AI, oncology and translational research to long experience in organizational leadership.